Analyst consensus rating
Gyre Therapeutics Analyst Rating: none
Direct answer
Gyre Therapeutics's consensus rating is none.
3 analysts are included in the current consensus when a coverage count is available.
The same consensus reports an average price target of $18.67.
Forecast evidence checked September 26, 2026.
Get free Gyre Therapeutics email updates.
Bullstory sends one daily email when new analysis or important company news is available.
Verified data
- Current price
- $7.35
- Average price target
- $18.67
- High price target
- $20.00
- Low price target
- $18.00
- Low target gap
- +144.9%
- Target upside
- +154%
- High target gap
- +172.1%
- Target range width
- 27.2%
- Consensus rating
- none
- Analysts
- 3
- Evidence date
- September 26, 2026
- Valid through
- October 3, 2026
Explore related company data
Read the frequently asked questions.
What is the analyst consensus rating for Gyre Therapeutics?
Gyre Therapeutics has a verified none consensus. The same dataset has an average price target of $18.67.
How far are Gyre Therapeutics's low and high targets from the recorded price?
The low target implies +144.9%, while the high target implies +172.1%.
How many analysts are included in Gyre Therapeutics's consensus?
The verified consensus includes 3 analysts.
How is Gyre Therapeutics's target upside or downside calculated?
The average target of $18.67 is divided by the recorded price of $7.35, then one is subtracted to produce +154%. This does not guarantee a future return.
When was Gyre Therapeutics's analyst forecast verified?
The data was verified on 2026-09-26. The dataset is valid through 2026-10-03.